Pipetting-driven microfluidic immunohistochemistry to facilitate enhanced immunoreaction and effective use of

Segi Kim1, Seyong Kwon1, Chang Hyun Cho1

  • 1Department of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology (KAIST), 291 Daehak-ro, Yuseong-gu, Daejeon 34141, Republic of Korea. jekyun@kaist.ac.kr.

Lab on a Chip
|February 2, 2017
PubMed

Insights

This study introduces a novel microfluidic immunohistochemistry (IHC) platform operated by a manual pipette. This easy-to-use system significantly reduces processing time and antibody waste for disease diagnosis.

Area of Science:

  • Biotechnology
  • Medical Diagnostics
  • Analytical Chemistry

Background:

  • Immunohistochemistry (IHC) is crucial for cancer diagnosis and research but is time-consuming and costly.
  • Existing microfluidic IHC platforms require specialized equipment, limiting real-world application.
  • Continuous flow in microfluidic systems leads to inefficient antibody use.

Purpose of the Study:

  • To develop a novel, user-friendly microfluidic IHC platform.
  • To eliminate the need for external pumps or controllers in microfluidic IHC.
  • To enhance antigen-antibody reactions and reduce antibody waste.

Main Methods:

  • A microfluidic IHC device operated solely by manual pipetting was developed.
  • Bidirectional fluid flow was induced via repetitive manual pipetting.
  • Breast cancer cell and tissue sections were stained using the developed platform.

Main Results:

  • The platform achieved effective immunostaining in under 2 minutes of pipetting.
  • Staining intensity was comparable to conventional IHC methods requiring 1 hour.
  • The system demonstrated efficient antibody utilization and sample preservation.

Conclusions:

  • The manual pipetting-based microfluidic IHC platform offers a convenient and accessible solution.
  • This approach simplifies microfluidic IHC for practical use in clinical and research settings.
  • The system enhances efficiency and reduces costs associated with IHC.